{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:42:48Z","timestamp":1778917368676,"version":"3.51.4"},"reference-count":84,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recently, significant progress has been made in identifying novel therapies, beyond conventional immunochemotherapy strategies, with efficacy in B-cell lymphomas. One such approach involves targeting the CD19 antigen on B cells with autologous-derived chimeric antigen receptor (CAR) cells. This strategy is highly effective in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), as evidenced by recent regulatory approvals. Recent reports suggest that this is an effective strategy for high-grade B-cell lymphoma. The biological underpinnings of these entities and how they overlap with each other and DLBCL continue to be areas of intense investigation. Therefore, as more experience with CAR T-cell approaches is examined, it is interesting to consider how both tumor cell\u2013specific and microenvironmental factors that define these highly aggressive subsets influence susceptibility to this approach.<\/jats:p>","DOI":"10.1182\/blood.2022016226","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T17:02:50Z","timestamp":1652461370000},"page":"1461-1469","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-515X","authenticated-orcid":false,"given":"Alaa","family":"Ali","sequence":"first","affiliation":[{"name":"1Stem Cell Transplant and Cellular Immunotherapy Program, Georgetown University, Washington, DC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"2John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"6769","key":"2022092915292147800_B1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"issue":"15","key":"2022092915292147800_B2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"2022092915292147800_B3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B\u00a0cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell."},{"issue":"5","key":"2022092915292147800_B4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"issue":"17","key":"2022092915292147800_B5","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood."},{"issue":"20","key":"2022092915292147800_B6","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022092915292147800_B7","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood."},{"issue":"35","key":"2022092915292147800_B8","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022092915292147800_B9","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood."},{"issue":"2","key":"2022092915292147800_B10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.16319","article-title":"Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy","volume":"189","author":"Landsburg","year":"2020","journal-title":"Br J Haematol."},{"issue":"12","key":"2022092915292147800_B11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clml.2016.08.017","article-title":"Clinical and pathologic correlation of increased MYC gene copy number in diffuse large B-cell lymphoma","volume":"16","author":"Haws","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"21","key":"2022092915292147800_B12","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.18632\/oncotarget.4073","article-title":"MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget."},{"issue":"5","key":"2022092915292147800_B13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3324\/haematol.2019.223891","article-title":"An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens","volume":"105","author":"Schieppati","year":"2020","journal-title":"Haematologica."},{"issue":"14","key":"2022092915292147800_B14","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/bloodadvances.2020001551","article-title":"Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"2022092915292147800_B15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022092915292147800_B16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","article-title":"The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood."},{"issue":"19","key":"2022092915292147800_B17","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood."},{"issue":"20","key":"2022092915292147800_B18","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood."},{"issue":"9","key":"2022092915292147800_B19","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2022092915292147800_B20","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood."},{"issue":"9","key":"2022092915292147800_B21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"2022092915292147800_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol."},{"issue":"23","key":"2022092915292147800_B23","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med."},{"issue":"23","key":"2022092915292147800_B24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med."},{"issue":"1","key":"2022092915292147800_B25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-015-0187-6","article-title":"Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas","volume":"7","author":"Sha","year":"2015","journal-title":"Genome Med."},{"issue":"3","key":"2022092915292147800_B26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022092915292147800_B27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature B-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica."},{"issue":"22","key":"2022092915292147800_B28","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large- B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med."},{"issue":"9","key":"2022092915292147800_B29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet."},{"issue":"3","key":"2022092915292147800_B30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00262-020-02708-3","article-title":"Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas","volume":"70","author":"Landsburg","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"2022092915292147800_B31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hon.2839","article-title":"High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: a possible noninflamed subgroup","volume":"39","author":"Breinholt","year":"2021","journal-title":"Hematol Oncol."},{"issue":"6","key":"2022092915292147800_B32","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov."},{"issue":"20","key":"2022092915292147800_B33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"3","key":"2022092915292147800_B34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00428-021-03050-4","article-title":"The \u201cBurkitt-like\u201d immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS","volume":"479","author":"H\u00fcttl","year":"2021","journal-title":"Virchows Arch."},{"issue":"1","key":"2022092915292147800_B35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pathol.2019.09.008","article-title":"High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification","volume":"52","author":"Ok","year":"2020","journal-title":"Pathology."},{"issue":"9","key":"2022092915292147800_B36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000818","article-title":"Further exploration of the complexities of large B-cell lymphomas with MYC abnormalities and the importance of a blastoid morphology","volume":"41","author":"Moore","year":"2017","journal-title":"Am J Surg Pathol."},{"issue":"16","key":"2022092915292147800_B37","first-page":"2196","article-title":"The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2022092915292147800_B38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11864-021-00857-w","article-title":"Novel biological insights and new developments in management of Burkitt lymphoma and high-grade B-cell lymphoma","volume":"22","author":"Lap","year":"2021","journal-title":"Curr Treat Options Oncol."},{"issue":"1","key":"2022092915292147800_B39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/hematology.2021000247","article-title":"Double-hit lymphoma: optimizing therapy","volume":"2021","author":"Dunleavy","year":"2021","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"key":"2022092915292147800_B40","article-title":"Defining and treating high-grade B-cell lymphoma, NOS","author":"Olszewski","year":"2021","journal-title":"Blood."},{"issue":"20","key":"2022092915292147800_B41","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022092915292147800_B42","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2022092915292147800_B43","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica."},{"issue":"12","key":"2022092915292147800_B44","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"issue":"8","key":"2022092915292147800_B45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"issue":"177","key":"2022092915292147800_B46","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med."},{"issue":"6","key":"2022092915292147800_B47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/1744666X.2021.1911648","article-title":"Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy","volume":"17","author":"Chaudhry","year":"2021","journal-title":"Expert Rev Clin Immunol."},{"key":"2022092915292147800_B48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.omtm.2021.09.008","article-title":"Novel TCR-like CAR-T cells targeting an HLA\u22170201-restricted SSX2 epitope display strong activity against acute myeloid leukemia","volume":"23","author":"Raskin","year":"2021","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"2022092915292147800_B49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-021-01161-4","article-title":"Engineered T cells: CAR T cell therapy and beyond","volume":"24","author":"Johnson","year":"2022","journal-title":"Curr Oncol Rep."},{"issue":"18","key":"2022092915292147800_B50","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood."},{"issue":"6","key":"2022092915292147800_B51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11899-019-00544-6","article-title":"Driving the CAR to the bone marrow transplant program","volume":"14","author":"Dave","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"issue":"11","key":"2022092915292147800_B52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"2022092915292147800_B53","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022092915292147800_B54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"2022092915292147800_B55","first-page":"40","article-title":"Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood."},{"issue":"27","key":"2022092915292147800_B56","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"27","key":"2022092915292147800_B57","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022092915292147800_B58","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"issue":"7","key":"2022092915292147800_B59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med."},{"issue":"7","key":"2022092915292147800_B60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med."},{"key":"2022092915292147800_B61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in Pati","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2022092915292147800_B62","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-cell lymphoma: who, when, and how?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med."},{"key":"2022092915292147800_B63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-134449","article-title":"Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL)","volume":"136","author":"Neelapu","year":"2020","journal-title":"Blood."},{"issue":"9","key":"2022092915292147800_B64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med."},{"issue":"4","key":"2022092915292147800_B65","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"6","key":"2022092915292147800_B66","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell."},{"issue":"19","key":"2022092915292147800_B67","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood."},{"issue":"6","key":"2022092915292147800_B68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2022092915292147800_B69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2022092915292147800_B70","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022092915292147800_B71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"issue":"9","key":"2022092915292147800_B72","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood."},{"issue":"10","key":"2022092915292147800_B73","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med."},{"issue":"10","key":"2022092915292147800_B74","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med."},{"issue":"7750","key":"2022092915292147800_B75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature."},{"issue":"5","key":"2022092915292147800_B76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"issue":"6","key":"2022092915292147800_B77","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"2022092915292147800_B78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell."},{"issue":"1","key":"2022092915292147800_B79","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/hematology.2020000133","article-title":"Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma","volume":"2020","author":"Hsieh","year":"2020","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"3","key":"2022092915292147800_B80","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv."},{"issue":"8","key":"2022092915292147800_B81","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00262-021-02850-6","article-title":"CAR19\/22 T cell therapy in adult refractory Burkitt\u2019s lymphoma","volume":"70","author":"Zhou","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"2","key":"2022092915292147800_B82","doi-asserted-by":"crossref","first-page":"142030","DOI":"10.1172\/JCI142030","article-title":"Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J Clin Invest."},{"issue":"1","key":"2022092915292147800_B83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"10254","key":"2022092915292147800_B84","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1461\/1922816\/bloodbld2022016226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1461\/1922816\/bloodbld2022016226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T15:31:06Z","timestamp":1664465466000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/13\/1461\/485238\/CAR-T-cell-therapy-in-highly-aggressive-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":84,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016226","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}